ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2274

Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse
Abstract Number: 2275

Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Abstract Number: 2276

Patient Reported Impact of Lupus on Quality of Life
Abstract Number: 2277

Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences
Abstract Number: 2278

Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Abstract Number: 2279

Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort
Abstract Number: 2280

The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Abstract Number: 2281

Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
Abstract Number: 2282

Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19
Abstract Number: 2283

Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Abstract Number: 2284

Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea
Abstract Number: 2285

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
Abstract Number: 2286

Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach
Abstract Number: 2287

Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic
Abstract Number: 2288

Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].